At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LTRN Lantern Pharma Inc.
Market Closed 02-14 16:00:00 EST
5.01
+0.18
+3.73%
盘后4.94
-0.07-1.40%
19:02 EST
High5.06
Low4.80
Vol76.03K
Open4.80
D1 Closing4.83
Amplitude5.38%
Mkt Cap54.03M
Tradable Cap39.90M
Total Shares10.78M
T/O374.70K
T/O Rate0.95%
Tradable Shares7.96M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
Lantern Pharma's Investigational Drug-Candidate, Lp-184, Receives Second Fast Track Designation From FDA for Treatment of Triple Negative Breast Cancer (Tnbc)
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Lantern Pharma & Starlight Therapeutics Present Lp-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.